• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MorphoSys AG (Amendment)

    3/8/24 3:58:16 PM ET
    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MOR alert in real time by email
    SC 13G/A 1 mora1_30824.htm KYNAM CAPITAL MANAGEMENT, LP mora1_30824.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    Morphosys AG
    (Name of Issuer)
    Common Stock
    (Title of Class of Securities)
    0D6632006
    (CUSIP Number)
    February 29, 2024
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 0D6632006
           
    1
    NAME OF REPORTING PERSON
    Kynam Capital Management, LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    85-3660072
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    4,190,331
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    4,190,331
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    4,190,331
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    11.13%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 0D6632006
           
    1
    NAME OF REPORTING PERSON
    Kynam Capital Management GP, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    85-3678691
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    4,190,331
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    4,190,331
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    4,190,331
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    11.13%
    12
    TYPE OF REPORTING PERSON
    OO
    CUSIP No.: 0D6632006
           
    1
    NAME OF REPORTING PERSON
    Yue Tang
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    4,190,331
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    4,190,331
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    4,190,331
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    11.13%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 0D6632006
    ITEM 1(a). NAME OF ISSUER:
    Morphosys AG
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    Semmelweisstr. 7
    82152 Planegg
    Germany
    ITEM 2(a). NAME OF PERSON FILING:
    Kynam Capital Management, LP
    Kynam Capital Management GP, LLC
    Yue Tang
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    221 Elm Road
    Princeton, NJ 08540
    United States of America
    ITEM 2(c). CITIZENSHIP:
    Delaware
    Delaware
    U.S.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock
    ITEM 2(e). CUSIP NUMBER:
    0D6632006
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    The below ownership figures include the listed entities and individuals ownership and control in CUSIP 617760202, MorphoSysAG ADR, adjusted to reflect the conversation ratio of 1 common share for every 4 ADRs.
    (a) Amount beneficially owned:
    4,190,331
    (b) Percent of class:
    11.13%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Kynam Capital Management, LP :

    Kynam Capital Management GP, LLC :

    Yue Tang :
    (ii) shared power to vote or to direct the vote:
    Kynam Capital Management, LP : 4,190,331

    Kynam Capital Management GP, LLC : 4,190,331

    Yue Tang : 4,190,331
    (iii) sole power to dispose or direct the disposition of:
    Kynam Capital Management, LP :

    Kynam Capital Management GP, LLC :

    Yue Tang :
    (iv) shared power to dispose or to direct the disposition of:
    Kynam Capital Management, LP : 4,190,331

    Kynam Capital Management GP, LLC : 4,190,331

    Yue Tang : 4,190,331
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 0D6632006
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    March 08 2024
    Kynam Capital Management, LP By: Kynam Capital Management GP, LLC, its General Partner
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Managing Member
    March 08 2024
    Kynam Capital Management GP, LLC
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Managing Member
    March 08 2024
    Yue Tang
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $MOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MOR

    DatePrice TargetRatingAnalyst
    3/14/2024Overweight → Equal Weight
    Wells Fargo
    1/16/2024$9.19 → $10.40Overweight → Equal-Weight
    Morgan Stanley
    10/13/2023$3.70 → $9.19Underweight → Overweight
    Morgan Stanley
    9/15/2023$3.50 → $9.25Sell → Neutral
    Goldman
    7/17/2023Sell → Hold
    Deutsche Bank
    6/16/2023$3.30 → $10.00Underweight → Overweight
    JP Morgan
    6/16/2023$17.00Overweight
    Wells Fargo
    5/31/2023Buy
    UBS
    More analyst ratings

    $MOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting

      MUNICH, GERMANY / ACCESSWIRE / August 27, 2024 / MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company's Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the transfer of MorphoSys' minority shareholders' shares to Novartis BidCo Germany AG (hereinafter referred to as "Novartis"), the company's majority shareholder, against a cash compensation of € 68.00 per share ("merger squeeze-out"). The merger squeeze-out will become effective once the transfer resolution and merger have been registered in the commercial register of MorphoSys, and the merger has also been registered in the commercial register of Novarti

      8/27/24 10:15:00 AM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

      MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares ("ADSs") from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act"). MorphoSys currently anticipates that it will file with the Securities and Exchange Commission (the "SEC") a Form 25, Notification of Removal of Listing and/or Registration Under Section 12(b) of the Exchange Act, relating to the delisting and deregistration on or about July 25, 2024, with the delisting of the ADSs taking effect no earlier than ten days thereafter. As a r

      7/12/24 4:59:00 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority Shareholders

      MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys' minority shareholders. In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders € 68.00 per share in cash (the "T

      6/20/24 2:47:00 AM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MOR
    Financials

    Live finance-specific insights

    See more
    • MorphoSys AG Reports First Quarter 2024 Financial Results

      – Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – Shareholder acceptance period for the Novartis offer has commenced and will end on May 13, 2024, at 24:00 hours CEST – Sold all tafasitamab rights worldwide to Incyte – € 631.9 million in cash and other financial assets as of March 31, 2024 MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the first quarter of 2024. "The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first hal

      4/29/24 4:01:00 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

      – Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value – Sold all tafasitamab rights worldwide to Incyte – Presented comprehensive Phase 3 MANIFEST-2 study results at ASH 2023 Annual Meeting, demonstrating pelabresib improves all four disease hallmarks of myelofibrosis – Monjuvi® U.S. net product sales of US$ 24.1 million (€ 22.4 million) for the fourth quarter of 2023 and US$ 92.0 million (€ 85.0 million) for the full year of 2023 – € 680.5 million in cash and other financial assets as of December 31, 2023 – MorphoSys to host conference call and webcast on Thursday, March 14, 2024, at 1:00 pm CET (12:00

      3/13/24 4:02:00 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

      Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available in the Investors section of the MorphoSys' website, www.morphosys.com.To join the conference call via pho

      3/7/24 4:04:00 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MOR
    Leadership Updates

    Live Leadership Updates

    See more
    • CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

      SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Sylvie Peltier ("Dr. Peltier") has been appointed as Senior Vice President of Global Regulatory Affairs of the Company with effect from October 31st, 2022. She will be responsible for developing global regulatory strategies, leading and driving the Company's regulatory affairs activities, and initiatives in support of IND/CTA/BLA filing and approval of developmental products globally. Dr. Peltier has extensive global leadership and hands-on experiences in cl

      10/31/22 9:30:00 AM ET
      $MOR
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters

      Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MorphoSys AG ((FSE: MOR, NASDAQ:MOR) announced today that Malte Peters, M.D., the company's Chief Research and Development Officer and Management Board member, has decided to retire at the end of 2022. His successor will be Tim Demuth, M.D., Ph.D., current Chief Medical Officer of Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company. Tim will start his new role on October 1. He will report to MorphoSys' CEO, Jean-Paul Kress, M.D., and be a member of the company's Executive Committee. At this time, Malte will step down from his operational responsibili

      8/31/22 4:01:00 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MorphoSys AG Reports Outcome of Annual General Meeting 2022

      PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual General Meeting which took place on Wednesday, May 18, 2022, including:- The discharge of the members of the Management and Supervisory Boards with respect to the 2021 financial year- The appointment of PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as auditor for the 2022 financial year- The election of Mr. Andrew Cheng, M.D., Ph.D., as Supervisory Board member- Resolution on the reduction of Conditional Capital 2016-III, Conditional Ca

      5/18/22 8:05:00 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by MorphoSys AG

      SC 13D/A - MorphoSys AG (0001340243) (Subject)

      8/15/24 4:30:06 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MorphoSys AG

      SC 13D/A - MorphoSys AG (0001340243) (Subject)

      6/21/24 4:30:07 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MorphoSys AG

      SC 13D/A - MorphoSys AG (0001340243) (Subject)

      6/17/24 4:30:09 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • MorphoSys downgraded by Wells Fargo

      Wells Fargo downgraded MorphoSys from Overweight to Equal Weight

      3/14/24 3:26:27 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MorphoSys downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded MorphoSys from Overweight to Equal-Weight and set a new price target of $10.40 from $9.20 previously

      1/16/24 7:51:32 AM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MorphoSys upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded MorphoSys from Underweight to Overweight and set a new price target of $9.20 from $3.70 previously

      10/13/23 7:18:44 AM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MOR
    SEC Filings

    See more
    • Amendment: SEC Form SC TO-T/A filed by MorphoSys AG

      SC TO-T/A - MorphoSys AG (0001340243) (Subject)

      8/13/24 4:31:16 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 14D9/A filed by MorphoSys AG

      SC 14D9/A - MorphoSys AG (0001340243) (Subject)

      8/7/24 4:51:56 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by MorphoSys AG

      SC TO-T/A - MorphoSys AG (0001340243) (Subject)

      8/7/24 4:30:52 PM ET
      $MOR
      Biotechnology: Pharmaceutical Preparations
      Health Care